PBI-4050, Prometic Life Sciences’ lead therapy candidate, works through a dual mechanism to target a newly discovered antifibrotic pathway, involving the receptors GPR40 and GPR84, that is critical to fibrosis development, a study shows.
The study, “A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84,” was published in the American Journal of Pathology.
Fibrosis occurs when there is an excessive accumulation of extracellular matrix (ECM) components in damaged or inflamed tissues, as a result of many inflammatory and metabolic diseases. There is a vital need for therapies that can effectively target biological pathways that lead to fibrosis.
